Sign in to view content

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2018

Related

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update
Glenn C. Yiu, MD, PhD
Updates from the Field
2025
Therapies for Diabetic Macular Edema: What’s in the Pipeline?
Peter K. Kaiser, MD FASRS
Updates from the Field
2018
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022

Category: Age-Related Macular Degeneration

See more